




RealRate

# PHARMACEUTICAL 2024

Ayala Pharmaceuticals Inc  
Rank 284 of 309

ADVAXIS  
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 7.5% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 161% points below the market average of 213%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 7,528                |
| Cost of Goods Sold                          | 13                   |
| Intangible Assets                           | 4,500                |
| Liabilities, Current                        | 25,018               |
| Liabilities, Non-Current                    | 15,978               |
| Other Assets                                | 4,011                |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | -3,912               |
| Other Liabilities                           | 0                    |
| Other Net Income                            | -15,718              |
| Other Revenues                              | 13                   |
| Property and Equipment                      | 540                  |
| Research and Development                    | 24,081               |
| Selling, General and Administrative Expense | 12,185               |

| Output Variable              | Value in<br>1000 USD |
|------------------------------|----------------------|
| Assets                       | 16,579               |
| Liabilities                  | 40,996               |
| Expenses                     | 32,367               |
| Revenues                     | 13                   |
| Stockholders Equity          | -24,417              |
| Net Income                   | -48,072              |
| Comprehensive Net Income     | -48,072              |
| BaseVar                      | 52,836               |
| ECR before Limited Liability | -352%                |
| Economic Capital Ratio       | 52%                  |